Prot #17403: A Randomized, Open Label, Multicenter Phase 2/3 Study to Evaluate the Efficacy and Safety of Rogaratinib (BAY 1163877) Compared to Chemotherapy in Patients with FGFR-Positive Locally Advanced or Metastatic Urothelial Carcinoma who Have Receiv

Project: Research project

Project Details

StatusActive
Effective start/end date3/29/195/30/22

Funding

  • Bayer HealthCare Pharmaceuticals, Inc. (Prot #17403)